Endothelin-1 in exhaled breath condensate of stable and unstable asthma patients  by Zietkowski, Z. et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 470–4740954-6111/$ - see fr
doi:10.1016/j.rmed.
Corresponding au
E-mail address: zSHORT SURVEY
Endothelin-1 in exhaled breath condensate of stable
and unstable asthma patients
Z. Zietkowski, R. Skiepko, M.M. Tomasiak, A. Bodzenta-LukaszykDepartment of Allergology and Internal Medicine, Medical University of Bialystok, Poland
Received 28 August 2007; accepted 24 October 2007
Available online 3 December 2007KEYWORDS
Endothelin-1;
Asthma;
Exhaled breath
condensate;
Exhaled nitric oxideont matter & 2007
2007.10.013
thor. Tel.: +48 85 7
.zietkowski@wp.pSummary
Endothelins are proinﬂammatory, proﬁbrotic, broncho- and vasoconstrictive peptides,
which play an important role in the development of airway inﬂammation and remodeling in
asthma. The study was undertaken to evaluate the endothelin-1 (ET-1) levels in exhaled
breath condensate (EBC) of asthmatics with different degree in asthma severity.
EBC was collected from 31 patients with allergic asthma (11 with steroid-naı¨ve mild
asthma, 10 with ICS-treated, stable mild-to-moderate asthma, 10 with ICS-treated
unstable, severe asthma) and 7 healthy volunteers.
In the three groups of asthmatics, ET-1 concentrations in EBC were signiﬁcantly higher than
in healthy volunteers. ET-1 levels were signiﬁcantly higher in patients with unstable
asthma than in the two groups with stable disease. There was a signiﬁcant correlation
between ET-1 levels and FENO in the three groups of asthmatics and between ET-1 and
blood eosinophil counts in the group of patients with unstable asthma.
Measurements of ET-1 in EBC may provide another useful diagnostic tool for detecting and
monitoring inﬂammation in patients with asthma.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Endothelins are a family of peptide mediators that have a
number of biological properties, including proinﬂammatory,
proﬁbrotic, broncho- and vasoconstrictive inﬂuence in hu-
man airways.1 Endothelin-1 (ET-1) has been demonstrated in
the airway epithelial and endothelial cells and is involved in
the pathogenesis of bronchial asthma.2,3 It has also beenElsevier Ltd. All rights reserved.
468373; fax: +48 85 7468601.
l (Z. Zietkowski).suggested that ET-1 inﬂuences asthmatic inﬂammation,
provoking the concentration and proliferation of bronchial
smooth muscle cells as well as subepithelial ﬁbrosis. This leads
to airway remodeling and severe bronchial hyperreactivity.4
Exhaled breath condensate (EBC), collecting by cooling
exhaled air, is non-invasive, easily performed, a rapid and
effort independent method for obtaining samples from the
lower respiratory tract. There has been increasing interest
in measuring EBC—a very useful method, especially in the
assessment of inﬂammatory mediators related to the
bronchial epithelium, in the pathophysiology and evaluation
of new strategies for the treatment of asthma.5
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ET-1 in EBC of stable and unstable asthma 471The aim of the study was to assess ET-1 concentrations in
the EBC of asthmatics with different degrees of asthmatic
severity, and to establish the possible correlation of these
measurements with the parameters of airway inﬂammation.
Material and methods
Patients
The study was conducted upon groups of 11 steroid-naı¨ve
mild allergic asthma patients, 10 patients treated with
inhaled corticosteroids (ICS) with stable mild-to-moderate
allergic asthma, and 10 ICS-treated patients with severe,
unstable allergic asthma. Asthma was diagnosed according
to the criteria recommended by the GINA 2002.6 The
steroid-naı¨ve asthmatics have not been treated with ICS
and were free from acute exacerbations and respiratory
tract infections during the 3 months prior to the study.
Patients with stable, mild-to-moderate asthma had been
treated with low to medium doses of ICS at a constant dose
for at least 3 months. Stable asthma was deﬁned as a
minimal need for rescue medications (short-acting b2-
agonists), no exacerbations, and no use of systemic steroids
in the previous 12 months. The patients with severe,
unstable asthma had required one or more hospitalizations
for asthma and more than three oral steroid bursts in the
last year. They had been taking high-doses of ICS and long-
acting b2-agonists for at least 6 months. Patients who had
respiratory tract infections in the last month before the
study were excluded from this study. All the patients were
atopic and sensitized to common inhaled allergens, as
evaluated by skin prick tests.
Seven healthy volunteers were used as a negative control
group. They were free of respiratory tract infection within
3 months prior to the study and from other signiﬁcant
illnesses known to affect exhaled nitric oxide (FENO)
measurements. Asthma patients and healthy volunteers
were non-smokers and during the last year have not been
passive smokers.
All of the patients and healthy volunteers were examined
by a physician, then underwent EBC collection, FENO
measurement, and spirometry. Blood samples were collected
to determine serum total IgE and blood eosinophil count.
The study protocol was approved by the Ethics of
Research Committee of the Medical University of Bialystok,
number of agreement: R-I-003/80/2006. Informed consent
was obtained from every patient entered into the study.
Measurements
Exhaled nitric oxide (FENO) was measured by the chemilu-
minescence technique using a Sievers 280i NO Analyzer
(Boulder, CO, USA). The measurements were performed at
an expiratory ﬂow of 50ml/s according to ATS recommenda-
tions for on-line measurement of FENO in adults.
7
The spirometry (FEV1) was performed using a MasterSc-
reen Pneumo PC spirometer (Jaeger, Hoechberg, Germany),
according to ATS standards.8
EBC was collected by using a commercially available
condenser (EcoScreen; Erich Jaeger GmbH) according to the
current ATS/ERS guidelines, as previously described.5,9,10Serum total IgE concentrations were measured using
ImmunoCAPTM Technology (Pharmacia Diagnostics, Uppsala,
Sweden). Blood eosinophil count was measured using a
hematologic analyzer (Coulter Electronics GmbH, Miami, FL,
USA). The concentrations of ET-1 in EBC were determined
using enzyme immunoassay kits for quantitative determina-
tion (ET-1-Biomedica Gruppe, Vienna, Austria). Detection
limit (0 fmol/ml+3 S.D.):0.02 fmol/ml.
Analysis
Statistical analyses were completed using the Student’s t-
test. All values were expressed as means7S.D.; p values
o0.05 were considered signiﬁcant. Correlations were
evaluated by Pearson’s linear correlation test.
Results
Characteristics of patients and healthy volunteers are
presented in Table 1.
In the three groups of asthmatics, EBC concentrations of
ET-1 were signiﬁcantly higher than those detected in healthy
volunteers (steroid-naı¨ve stable asthma: 0.8870.24 fmol/ml,
p ¼ 0.017; ICS-treated stable asthma: 0.9970.23 fmol/ml,
p ¼ 0.0018; unstable asthma: 2.2770.82 fmol/ml, p ¼
0.0001; healthy volunteers: 0.5970.19 fmol/ml) (Figure 1).
ET-1 levels were signiﬁcantly elevated in patients with
unstable asthma compared with ICS-treated stable asthma
patients (p ¼ 0.00018) and steroid-naı¨ve asthma patients
(p ¼ 0.0004). There was no signiﬁcant difference (p ¼ 0.29)
in ET-1 concentrations between stable ICS-treated and
steroid-naı¨ve asthma patients.
We revealed statistically signiﬁcant correlations between
concentrations of ET-1 in EBC and FENO in the three
studied groups of asthmatics; the degree of correlation
increased as asthma severity intensiﬁed. There were no
correlations between ET-1 in EBC and FENO in the group of
healthy volunteers. We discovered a signiﬁcantly positive
correlation between ET-1 in EBC and blood eosinophil count
in the groups of asthmatics with severe, unstable asthma.
There was no statistically signiﬁcant correlation between
ET-1 in EBC and other studied parameters in any of
the studied groups of asthmatics and healthy volunteers
(Table 2).
Discussion
There have been numerous studies investigating whether
differences exist between asthmatics and non-asthmatic
volunteers, especially with regard to the expression of ET-1
by cultured airway epithelial cells, as well as the levels
of ET-1 in saliva, sputum, plasma, BAL ﬂuid, and bronchial
biopsy specimens.11–13 Furthermore, the relationship
between levels of ET-1 and markers of airway inﬂamma-
tion and bronchial reactivity has also been the object
of several studies.4,14,15 The inﬂuence of anti-inﬂammatory
therapy on levels of ET-1 has been investigated as well.16–18
In human airways, immunoreactive ET-1 is located
principally in the bronchial epithelium. Expression at this
site increases with asthma and is correlated with the
severity of the disease.16 Except for human bronchial
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Table 1 Characteristics of study subjects and healthy volunteers.
Characteristics Healthy
volunteers
Stable asthma,
steroid naı¨ve
Stable asthma,
ICS-treated
Unstable asthma
No. of patients 7 11 10 10
Sex (F/M) 4/3 6/5 6/4 7/3
Age (years) 28.0074.93 27.3677.50 44.7078.11 45.9076.04
Duration of symptoms (years) 2.5471.21y,z 8.6073.86,z 16.977.04,y
Baseline FEV1 (% predicted) 106.8579.7
y,z 95.63718.54z 83.6076.61z 56.70712.46,y
Serum total IgE concentration (kU/l) 65.42731.65,y,z 327.97265.6 275.0788.60 315.07123.5
Blood eosinophil count (cells/mm3) 51726,y,z 2397138 271770 3027104
FENO (ppb) 18.0075.59
,y,z 76.00733.66y 38.70710.26,z 74.80728.64y
ET-1 (fmol/ml) 0.5970.19,y,z 0.8870.24z 0.9970.23z 2.2770.82,y
Data are presented as medians (ranges). FEV1: forced expiratory volume in 1 s.
Values signiﬁcantly different from patients with stable, steroid-naı¨ve asthma, po0.05.
yValues signiﬁcantly different from patients with stable, ICS-treated asthma, po0.05.
zValues signiﬁcantly different from patients with unstable asthma, po0.05.
Figure 1 Concentrations of ET-1 in EBC in studied groups of asthma patients and healthy volunteers.
Table 2 Correlations between concentrations ET-1 in EBC and other studied parameters in the groups of asthma patients and
healthy volunteers.
Studied groups FENO Blood eosinophil count Serum total IgE Baseline FEV1
Healthy volunteers r ¼ 0.38 r ¼ 0.48 r ¼ 0.22 r ¼ 0.53
p ¼ 0.39 p ¼ 0.11 p ¼ 0.62 p ¼ 0.22
Stable asthma steroid-naı¨ve r ¼ 0.73 r ¼ 0.26 r ¼ 0.17 r ¼ 0.24
p ¼ 0.01 p ¼ 0.42 p ¼ 0.61 p ¼ 0.46
Stable asthma ICS-treated r ¼ 0.94 r ¼ 0.47 r ¼ 0.48 r ¼ 0.12
p ¼ 0.00005 p ¼ 0.16 p ¼ 0.15 p ¼ 0.73
Unstable asthma r ¼ 0.94 r ¼ 0.67 r ¼ 0.43 r ¼ 0.47
p ¼ 0.00005 p ¼ 0.03 p ¼ 0.07 p ¼ 0.16
Z. Zietkowski et al.472epithelial cells,19 ET-1 is produced by vascular endo-
thelial cells,1 as well as inﬂammatory cells such as
macrophages20 and mast cells.21Many interactions between ET-1 and other cytokines
essential in asthma have been described. Tumor necrosis
factor-a (TNF-a) induces secretion of ET-1 from cultured
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of granulocyte-macrophage colony-stimulating factor
(GM-CSF) in human lung ﬁbroblasts and through this could
directly affect recruitment of eosinophils in the airways.22
ET-1 also stimulates monocytes to release GM-CSF, IL-6, IL-8,
IL-1, TNF-a and TGF-a.23 The interaction between ET-1 and
other cytokines which are growth factors for bronchial
subepithelial myoﬁbroblasts, may play a key role in
remodeling in asthmatic patients, which is the consequence
of repeated episodes of epithelial damage and repair in
asthmatic inﬂammation.24
ET-1 may contribute signiﬁcantly to the remodeling of the
airway by slowing epithelial cell migration while increasing
the proliferation of airway ﬁbroblasts and smooth muscle
cells. The damage of asthmatic airways by environmental
agents and allergens may be additionally increased by
slower repair mechanisms, in which ET-1 may be involved.25
EBC examination being simple and non-invasive could be
exploited to detect speciﬁc levels of biomarkers and
monitor disease severity in response to appropriate pre-
scribed therapy.9 There are two reports concerning elevated
ET-1 levels in EBC in patients with ﬁbrosing lung disease and
lung cancer.26,27 However, there are no reports about using
EBC for the assessment of ET-1 levels in asthma patients.
Our study shows that ET-1 levels in EBC are higher in
asthmatic patients than in healthy controls. The concentra-
tions of ET-1 increase as the severity of asthma is
augmented. In patients with unstable asthma, levels of
ET-1 were signiﬁcantly higher than in steroid-naı¨ve and
ICS-treated patients with stable asthma. The level of ET-1,
depending on the severity of the asthma, signiﬁcantly
correlated with other inﬂammatory markers. We have
uncovered no signiﬁcant difference in ET-1 levels between
steroid-naı¨ve mild asthmatics and ICS-treated mild-to-
moderate asthmatics. This could suggest the beneﬁcial
effect of ICS-treatment in downregulation of ET-1 in the
airways. However, more studies are needed to assess the
inﬂuence of ICS on ET-1 levels in EBC.
What is the possible reason of the elevated ET-1 levels in
unstable asthma? A number of studies have reported, that in
severe asthma, the several proinﬂammatory cytokines
including TNF-a and TGF-b can induce the inﬂammatory
cascade reaction, which may lead to airway hyperrespon-
siveness and structural changes characteristic for severe
asthma. The mechanism of increase in ET-1 level could be
not only the consequence of promoting the interaction
between cytokines, but also of higher expression of this
cytokine on inﬂammatory modiﬁed bronchial epithelium
cells and stimulating ET-1 secretion, resulting in its elevated
levels in the airways. The increased levels of ET-1 in patients
with unstable asthma can be also associated with the rise in
the number of inﬂammatory cells involved in ET-1 produc-
tion (e.g. macrophages, mast cells).28,29
He et al. revealed that ET-1 expression in bronchial
mucosa was still high in patients with severe asthma who
had a poor response to ICS. It is indicated that the airway
hyperresponsiveness in patients with severe asthma might
be associated with stronger expression of ET-1.30
Measurements of ET-1 in EBC of asthma patients may
provide another useful diagnostic tool for detecting and
monitoring inﬂammation, disease severity, and response to
the treatment.Competing interests
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